TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30892603

Group type: EXPERIMENTAL
Intervention: PUVA induction regimen (oral 8-methoxypsoralen followed by UV-A exposure 2 times per week for 12 to 24 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PUVA maintenance treatment (14 total exposures for 9 months)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Baseline characteristics (high density of histologic infiltrate and high percentage of clonal TCR sequences in skin biopsy specimens)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PUVA induction and maintenance phases
Number of subjects: 27
Study: 29156910

Group type: EXPERIMENTAL
Intervention: Single 8-Gy RT for painful bone metastases
Number of subjects: 52
Study: 25417709

Group type: EXPERIMENTAL
Intervention: Daily oral conjugated equine estrogen (oCEE, 0.45 mg)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Weekly transdermal 17β‐estradiol (tE2, 50 μg)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo pills and patch
Number of subjects: 83
Study: 23884353

Group type: EXPERIMENTAL
Intervention: AMG145 70 mg every 2 weeks
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: AMG145 105 mg every 2 weeks
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: AMG145 140 mg every 2 weeks
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: AMG145 280 mg every 4 weeks
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: AMG145 350 mg every 4 weeks
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: AMG145 420 mg every 4 weeks
Number of subjects: 631

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study: 21091270

Group type: EXPERIMENTAL
Intervention: Olmesartan (O) 10 mg once daily, with potential dose increase to 40 mg
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Olmesartan (O) 10 mg once daily
Number of subjects: 351

Group type: COMPARATOR
Intervention: Ramipril (R) 2.5 mg once daily, with potential dose increase to 10 mg
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Olmesartan (O)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Ramipril (R)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Olmesartan (O) and Ramipril (R)
Number of subjects: 351
Study: 19505206

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17482847

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (n=9)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Surgical therapy (n=7)
Number of subjects: 16
Study: 15124990

Group type: EXPERIMENTAL
Intervention: AGIMRT (6.5 Gy and 1.8 Gy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AGIMRT
Number of subjects: 10

Group type: COMPARATOR
Intervention: HDR
Number of subjects: 10
Study: 11773175

Group type: EXPERIMENTAL
Intervention: 18 Gy of cranial irradiation (hyperfractionated)
Number of subjects: 369

Group type: COMPARATOR
Intervention: 18 Gy of cranial irradiation (conventionally fractionated)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Not applicable (standard-risk patients did not receive cranial irradiation)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Not applicable (high-risk/very high-risk patients received cranial irradiation)
Number of subjects: 369
Study: 9551595

Group type: EXPERIMENTAL
Intervention: abciximab (ReoPro; Lilly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: low-dose or standard-dose weight-adjusted heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: abciximab, eptifibatide (INTEGRILIN; Cor/Schering), tirofiban
Number of subjects: 0
Study: 8123633

Group type: EXPERIMENTAL
Intervention: Intraocular irrigation fluid with 1:1,000,000 adrenaline
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (intraocular irrigation fluid without adrenaline)
Number of subjects: 70
Study: 2561042

Group type: EXPERIMENTAL
Intervention: CO2-laser vaporization
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Combined lesions (HPV‐CIN & HPV‐VAIN) treated by laser
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cryotherapy and CO2-laser vaporization
Number of subjects: 119
Study: 24980

Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fosazepam 60 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 17
Study: 30981954

Group type: EXPERIMENTAL
Intervention: Oxfendazole, administered as multiple oral doses, specific dosage not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albendazole, used as an internal standard in the assay.
Number of subjects: 0
Study: 26231151

Group type: EXPERIMENTAL
Intervention: Pilates exercise group (n = 24)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 26)
Number of subjects: 50
Study: 25038874

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: HER2-positivity analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: HER2 testing
Number of subjects: 0
Study: 23269720

Group type: EXPERIMENTAL
Intervention: Long-axis in-plane technique
Number of subjects: 46

Group type: COMPARATOR
Intervention: Short-axis in-plane technique
Number of subjects: 46
Study: 23271905

Group type: EXPERIMENTAL
Intervention: High-intensity noninvasive ventilation (high-pressure and high backup rate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-pressure noninvasive ventilation (high-pressure and low backup rate)
Number of subjects: 12
Study: 19389743

Group type: EXPERIMENTAL
Intervention: Tai Chi Qigong training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 44
Study: 17430732

Group type: EXPERIMENTAL
Intervention: Submucous myomas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uterine myomas
Number of subjects: 0
Study: 15471149

Group type: EXPERIMENTAL
Intervention: Biventricular stimulation (cardiac resynchronization therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11520379

Group type: EXPERIMENTAL
Intervention: Focused 20-minute educational session on evaluation and feedback, accompanied by 3 by 5 reminder card and diary, given to faculty at the start of their attending month.
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (faculty not receiving the educational intervention).
Number of subjects: 157
Study: 9749780

Group type: EXPERIMENTAL
Intervention: Layer V dendritic pattern
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Layer IIIc neurons
Number of subjects: 8
Study: 7831649

Group type: EXPERIMENTAL
Intervention: Fragmin (low molecular weight heparin) administered subcutaneously once daily at a fixed dose of 200 IU anti-factor Xa/kg
Number of subjects: 204

Group type: COMPARATOR
Intervention: Continuous intravenous infusion of unfractionated heparin (UFH)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Fragmin
Number of subjects: 204

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 204
Study: 2966546

Group type: EXPERIMENTAL
Intervention: Enoximone 1 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enoximone 2 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29112086

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30187734

Group type: EXPERIMENTAL
Intervention: IBA 0.25 mg L‐1 and kinetin 1 mg L‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control treatment (no added NAA and IBA)
Number of subjects: 8
Study: 26290236

Group type: COMPARATOR
Intervention: Chronic pain patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Healthy human subjects
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Individual responsiveness of the external‐task‐positive ventrolateral prefrontal cortex
Number of subjects: 51
Study: 23139428

Group type: EXPERIMENTAL
Intervention: General exercise
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Motor control exercise
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 182
Study: 21498915

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Voglibose
Number of subjects: 60
Study: 18803795

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (pill)
Number of subjects: 628
Study: 16979701

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 746

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 746
Study: 12684357

Group type: EXPERIMENTAL
Intervention: Commercial weight loss program (n = 211) consisting of a food plan, activity plan, and cognitive restructuring behavior modification plan, delivered at weekly meetings.
Number of subjects: 423

Group type: COMPARATOR
Intervention: Self-help program (n = 212) consisting of two 20-minute counseling sessions with a nutritionist and provision of self-help resources.
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Commercial weight loss program
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 423
Study: 11022850

Group type: EXPERIMENTAL
Intervention: High flavonoid diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low flavonoid diet
Number of subjects: 0
Study: 8957573

Group type: EXPERIMENTAL
Intervention: Cotrifazid (rifampicin+isoniazid+sulfamethoxazole+trimethoprim)
Number of subjects: 61
Study: 1549990

Group type: EXPERIMENTAL
Intervention: Streptokinase (1,500,000 units over 1 hour)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: rTPA (100 mg over 3 hours)
Number of subjects: 122

Group type: COMPARATOR
Intervention: rTPA
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 122
Study: 3698694

Group type: EXPERIMENTAL
Intervention: Incentive spirometry (encouraged by a specialized respiratory physiotherapist to breathe deeply for five minutes hourly, 12 times daily, for three postoperative days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specialized postoperative respiratory care)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 40
Study: 29679432

Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: varenicline + bupropion
Number of subjects: 385

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 385
Study: 27322812

Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol (HT) supplementation for 8 weeks in rodents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxytyrosol (HT) supplementation in healthy volunteers
Number of subjects: 0
Study: 24804788

Group type: EXPERIMENTAL
Intervention: Extrinsic visual signal (rotary motion direction of an annulus of random dots)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extrinsic auditory signal (direction of an auditory pitch glide)
Number of subjects: 0
Study: 23104212

Group type: EXPERIMENTAL
Intervention: MSI-high status
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: SMAD4 focal loss of expression
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: 18qLOH
Number of subjects: 1404
Study: 20921834

Group type: EXPERIMENTAL
Intervention: Dextrose 5% in water (D5W) injection before catheter placement
Number of subjects: 70

Group type: COMPARATOR
Intervention: No injection (Control)
Number of subjects: 70
Study: 18514618

Group type: EXPERIMENTAL
Intervention: Special oral nutritional mixture of amino acids (AAs) 4 g twice daily (n = 43)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (n = 42)
Number of subjects: 95
Study: 16781338

Group type: EXPERIMENTAL
Intervention: Topical minocycline (1.0 mg in bioresorbable polyglycolide‐co‐dl‐lactide [PGLA] sustained‐release microspheres)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Topical minocycline
Number of subjects: 63
Study: 14585449

Group type: COMPARATOR
Intervention: Antacid (Group 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Antacid + Donnatal (Group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Antacid + Donnatal + viscous lidocaine (Group 3)
Number of subjects: 120
Study: 10634370

Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9039715

Group type: EXPERIMENTAL
Intervention: Methylprednisolone suleptanate
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate
Number of subjects: 88
Study: 1578954

Group type: EXPERIMENTAL
Intervention: BHAC-DMP + VCR 0.35 mg/m2 on days 1-4
Number of subjects: 258

Group type: COMPARATOR
Intervention: BHAC-DMP
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Maintenance therapy of 12 courses
Number of subjects: 258

Group type: COMPARATOR
Intervention: Maintenance therapy of 4 courses
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Event-free survival (EFS)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Continuing CR rate
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Disease-free survival (DFS)
Number of subjects: 258
Study: 2579801

Group type: EXPERIMENTAL
Intervention: Primed words (preceded by a semantically related word)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unprimed words (preceded by semantically unrelated words or nonwords)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ERPs for primed words
Number of subjects: 0

Group type: COMPARATOR
Intervention: ERPs for unprimed words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P300 latency
Number of subjects: 0
Study: 30541074

Group type: EXPERIMENTAL
Intervention: Left atrial peak reservoir strain (LA RS)
Number of subjects: 385
Study: 27869485

Group type: EXPERIMENTAL
Intervention: Yoga intervention (90-min sessions, twice a week for 8 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no yoga)
Number of subjects: 40
Study: 27303937

Group type: EXPERIMENTAL
Intervention: Biangulation technique
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Triangulation technique
Number of subjects: 32
Study: 24485056

Group type: EXPERIMENTAL
Intervention: Rotational offsets of 1°, 3°, and 5° in roll, yaw, and pitch
Number of subjects: 11
Study: 22897901

Group type: EXPERIMENTAL
Intervention: TeamCare intervention
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 168
Study: 19249048

Group type: EXPERIMENTAL
Intervention: 800 microg of rectal misoprostol
Number of subjects: 514

Group type: COMPARATOR
Intervention: 5 IU of intravenous oxytocin
Number of subjects: 514
Study: 17432679

Group type: EXPERIMENTAL
Intervention: Acupuncture plus rehabilitation training (Bobath and Vojta methods)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rehabilitation training (Bobath and Vojta methods)
Number of subjects: 100
Study: 14747203

Group type: EXPERIMENTAL
Intervention: Ultrasound-based strategy (glycemia plus ultrasound)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard management (maternal glycemia alone)
Number of subjects: 199
Study: 11498311

Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg rocuronium
Number of subjects: 51

Group type: COMPARATOR
Intervention: 0.5 mg/kg atracurium
Number of subjects: 51
Study: 9662821

Group type: EXPERIMENTAL
Intervention: Erythromycin, 500 mg orally twice a day for 15-14 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Combination of recombinant alpha 2‐interferon with complex immunoglobulin preparation (CTP), vaginal suppositories containing 300 mg of CTP and intravaginal application of 15(2)-30 ml of solution containing 2.0 x 10(6) I.U. of recombinant alpha 2‐interferon
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Combination of recombinant alpha 2‐interferon with complex immunoglobulin preparation (CTP)
Number of subjects: 61
Study: 7810790

Group type: EXPERIMENTAL
Intervention: Over the top graft placement
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Through the femoral condyle graft placement
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 87
Study: 3276298

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (after placebo group received it)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined analysis of all patients receiving cyclophosphamide
Number of subjects: 14
Study: 30864000

Group type: EXPERIMENTAL
Intervention: Schema training at the outset of learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher ratio of worked examples to problem-solving practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Schema training after problem-solving practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower ratio of worked examples to problem-solving practice
Number of subjects: 0
Study: 29587687

Group type: EXPERIMENTAL
Intervention: Above-elbow cast (AE)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Below-elbow cast (BE)
Number of subjects: 128
Study: 28028319

Group type: EXPERIMENTAL
Intervention: Educational intervention involving motivational interviews with parents and teacher-led learning experiences for children.
Number of subjects: 425

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Educational intervention (I).
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: BMI outcomes (I).
Number of subjects: 425
Study: 26039952

Group type: EXPERIMENTAL
Intervention: Limberg flap technique
Number of subjects: 71

Group type: COMPARATOR
Intervention: Karydakis flap technique
Number of subjects: 71
Study: 24134550

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (Healthy men)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Metformin and Pioglitazone
Number of subjects: 78
Study: 21318734

Group type: EXPERIMENTAL
Intervention: Quiet Eye (QE) training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo group (no instruction)
Number of subjects: 20
Study: 19884428

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 86

Group type: COMPARATOR
Intervention: Nonresurfacing of the patella
Number of subjects: 86
Study: 16504859

Group type: EXPERIMENTAL
Intervention: Tissue-engineered bone (autogenous osteoblasts cultured on demineralized bone matrix Osteovit)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spongiose iliac bone
Number of subjects: 20
Study: 15299049

Group type: EXPERIMENTAL
Intervention: Image fusion of CT and PET
Number of subjects: 104

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 104

Group type: COMPARATOR
Intervention: PET alone
Number of subjects: 104
Study: 10884648

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion at 1 microg. kg(‐1). min(‐1) starting 10 minutes before cardiopulmonary bypass and maintained for 4 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion
Number of subjects: 20
Study: 9605251

Group type: EXPERIMENTAL
Intervention: Gestational age at delivery
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Duration of painful labor
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Duration of antenatal antibiotic therapy
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Maternal age
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Factor X activity in umbilical cord blood
Number of subjects: 353

Group type: COMPARATOR
Intervention: Mode of delivery
Number of subjects: 353

Group type: COMPARATOR
Intervention: Cord blood acid-base status
Number of subjects: 353

Group type: COMPARATOR
Intervention: Coagulation status
Number of subjects: 353
Study: 8350001

Group type: EXPERIMENTAL
Intervention: Layered closure technique
Number of subjects: 34

Group type: COMPARATOR
Intervention: Mass closure technique
Number of subjects: 34
Study: 2873967

Group type: EXPERIMENTAL
Intervention: Oral astemizole (30 mg during the first week, then 10 mg for the rest of the study period)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Topical sodium cromoglycate (2%, administered 6-times daily intranasally and 4-times daily in the eyes)
Number of subjects: 95
Study: 31783231

Group type: EXPERIMENTAL
Intervention: Zhang's guideline
Number of subjects: 7277

Group type: COMPARATOR
Intervention: WHO partograph
Number of subjects: 7277
Study: 30194500

Group type: EXPERIMENTAL
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 163
Study: 28161387

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin (20IU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26419824

Group type: EXPERIMENTAL
Intervention: Mifepristone plus Misoprostol
Number of subjects: 110

Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 110
Study: 23451243

Group type: EXPERIMENTAL
Intervention: Propranolol (PROP) 80 mg administered 60 minutes prior to stress exposure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol (PROP)
Number of subjects: 30
Study: 21336835

Group type: EXPERIMENTAL
Intervention: Carbetocin (100 μg, single intramuscular dose)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Syntometrine (single intramuscular dose)
Number of subjects: 240
Study: 19172538

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg) plus methyl-testosterone (1.25 mg) and micronised progesterone (100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16246545

Group type: COMPARATOR
Intervention: CPT‐11 administered at 180 mg/m2 on day 1, by 1‐h infusion (Arm A)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 6‐h sinusoidal infusion of CPT‐11 with peak timing at 5:00 a.m. (Arm B)
Number of subjects: 68